P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR566 Final Exam –
Advanced Pharmacology
Verified Q&A & Question
Bank (2026 Edition)
Verified Answers Exam Ready With Rationales
107 QUESTIONS
DOCUMENT OVERVIEW
This document features 107 verified questions with correct answers and detailed rationales focused on
advanced pharmacology. It serves as a comprehensive resource for understanding pharmacological
concepts and applications in clinical practice. Students can utilize it for effective study, review, and
preparation for certification exams in the field.
CONTENTS
01 Hormonal Therapies Q1–Q11
02 Antibiotic Treatments Q12–Q17
03 Parkinson's Disease Management Q18–Q31
04 Migraine Management Q32–Q43
Page 1
, 05 Alzheimer's Disease Treatments Q44–Q52
06 Bipolar Disorder and Mood Stabilizers Q53–Q65
07 Antidepressant Medications Q66–Q76
08 Anxiety Disorders Treatments Q77–Q96
09 Additional Questions Q97–Q107
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 107
Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
CORRECT ANSWER
alternatives for hormone replacement therapy
RATIONALE
Raloxifene and bisphosphonates serve as non-hormonal options for preventing and treating osteoporosis by
modulating bone metabolism, thereby reducing fracture risk without the associated risks of hormone replacement
therapy. This highlights the principle of utilizing alternative pharmacological strategies to manage osteoporosis in
postmenopausal women.
Q2 QUESTION 2 OF 107
Selective Estrogen Receptor Modulators (SERMs)
CORRECT ANSWER
Tamoxifen, toremifene, raloxifene -- provide estrogen benefits while avoiding its drawbacks
RATIONALE
SERMs selectively bind to estrogen receptors, mimicking estrogen's beneficial effects on bone density and lipid
profiles while antagonizing its proliferative effects in breast tissue. This dual action allows for therapeutic advantages
in conditions like osteoporosis and breast cancer without the associated risks of traditional estrogen therapy.
Q3 QUESTION 3 OF 107
Page 2
,Dysfunctional uterine bleeding
CORRECT ANSWER
10-14 day course of progestin
RATIONALE
Progestins regulate the endometrial lining and promote its shedding, effectively managing hormonal imbalances that
lead to dysfunctional uterine bleeding. A 10-14 day course provides sufficient duration for stabilizing the cycle and
alleviating excessive bleeding.
Q4 QUESTION 4 OF 107
Amenorrhea treatment
CORRECT ANSWER
progestin helps induce menstrual flow
RATIONALE
Progestin therapy induces menstrual flow by mimicking the natural hormonal cycle, specifically promoting the
shedding of the endometrial lining in cases of anovulation. This approach is key in managing amenorrhea caused by
hormonal imbalances, thereby restoring regular menstrual patterns.
Q5 QUESTION 5 OF 107
Amenorrhea estrogen levels are low
CORRECT ANSWER
give progestin for 5-10 days
RATIONALE
Administering progestin for 5-10 days induces withdrawal bleeding by mimicking the luteal phase of the menstrual
cycle, which is necessary when estrogen levels are low and amenorrhea is present. This approach helps assess the
endometrial response and rule out potential underlying conditions.
Q6 QUESTION 6 OF 107
Page 3
, Long term progestin therapy
CORRECT ANSWER
protection against endometrial cancer
RATIONALE
Long-term progestin therapy counteracts unopposed estrogen stimulation of the endometrium, significantly reducing
the risk of hyperplasia and subsequent endometrial carcinoma. This protective effect is particularly important in
women with a uterus undergoing estrogen replacement therapy.
Q7 QUESTION 7 OF 107
Estradiol
CORRECT ANSWER
most active estrogenic compound. oral estrogen option
RATIONALE
Estradiol serves as the most potent estrogen, playing a critical role in regulating reproductive processes and
secondary sexual characteristics; its oral formulation provides a convenient method for hormone replacement therapy
or contraceptive use. This highlights the importance of understanding the pharmacological profiles of estrogen
compounds in clinical practice.
Q8 QUESTION 8 OF 107
Advantages of estrogen transdermal patch
CORRECT ANSWER
lower total estrogen dose. less n/v. less fluctuation of estrogen blood levels. lower r/f DVT, PE and stroke
RATIONALE
Transdermal estrogen delivery provides a more stable plasma concentration, minimizing fluctuations that can lead to
side effects such as nausea and reducing the risk of thromboembolic events compared to oral administration.
Additionally, the lower total estrogen dose required with patches decreases the exposure and associated risks.
Q9 QUESTION 9 OF 107
Page 4